Obstetrics & Gynecology

News and Events

Programs and providers of Obstetrics and Gynecology at Weill Cornell Medicine are often the focus of news stories and features appearing in major national media. We invite you to review some stories that typify the breakthrough accomplishments of our remarkable team and highlight the impact our care has had on patient’s lives.

Convocation Honors Graduate Students’ Achievements

graduate students

Weill Cornell Graduate School of Medical Sciences celebrated students in the Class of 2025 for their academic achievements during its May 14 convocation ceremony.

The ceremony honored students who are graduating with their master’s degrees, as well as those who earned special awards and prizes for their accomplishments in research, scholarship and service. The ceremony also recognized exemplary graduate school faculty.

Dr. Ting Jia (Ph.D. ’08), founder and managing member of Octagon Capital, won the 2025 Weill Cornell Graduate School of Medical Sciences Award of Distinction. This award honors alumni who have demonstrated exceptional achievements and outstanding contributions to biomedical research and education.

2025 Award Winners:

DISTINGUISHED STUDENT COMMENCEMENT SPEAKER AWARD

Chiara D. Mancinelli
Pharmacology Program
(Mentor: David Eliezer, Ph.D.)

JULIAN R. RACHELE PRIZE

Mir Zainab Howlader, “Lymphatic Dysfunction in Lupus Contributes to Cutaneous Photosensitivity And Lymph Node B Cell Responses.” Journal of Clinical Investigation. (Mentor: Dr. Theresa T. Lu, M.D., Ph.D.)

Kathleen Mills, “GM-CSF-Mediated Epithelial-Immune Cell Cross-Talk Orchestrates Pulmonary Immunity to Aspergillus fumigatus.” Science Immunology. (Mentor: Dr. Tobias Hohl, M.D., Ph.D.). 

Head-to-Head Trial Compares Weight Loss Drugs

man in a t-shirt holding a tape measure around his waist

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the injectable drugs. In the 72-week trial—led by an investigator at Weill Cornell Medicine and NewYork-Presbyterian and conducted with the University of Texas McGovern Medical School, the David Geffen School of Medicine at the University of California, Los Angeles, the University College Dublin and Eli Lilly—participants taking tirzepatide lost about 50 pounds—or 20.2% of their body weight—compared with those on semaglutide, who lost an average of 33 pounds or 13.7% of their baseline weight.

The results of the SURMOUNT-5 phase 3b study, published May 11 in the New England Journal of Medicine, showed that when both drugs are administered at their maximum doses, participants receiving tirzepatide were more likely to reach weight loss targets and saw a greater reduction in waist circumference than those on semaglutide.

AI Tool Accurately Sorts Cancer Patients by their Likely Outcomes

finger pointing to colorful image of networks

A new artificial intelligence-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar outcomes after treatment, according to a study led by investigators at Weill Cornell Medicine. The new approach has the potential to enable better patient selection in clinical trials and better treatment selection for individual patients.

The study, published May 12 in Nature Communications, was a collaboration with Regeneron Pharmaceuticals, and addressed a problem that many pharma companies and physicians face: how to predict which patients will have the best responses to a drug. The results showed that the new method’s ability to predict treatment outcomes from health record data was better than that of any other method published to date.

Dr. Fei Wang

Dr. Fei Wang

Contact Us